Should EGFR mutations be tested in advanced lung squamous cell carcinomas to guide frontline treatment? Chao-Hua ChiuTeh-Ying ChouChun-Ming Tsai Review Article 23 July 2014 Pages: 661 - 665
Pharmacogenetics of adjuvant breast cancer treatment with cyclophosphamide, epirubicin and 5-fluorouracil David JamiesonJo LeeAlan V. Boddy Original Article 24 July 2014 Pages: 667 - 674
Risk and outcomes of chemotherapy-induced diarrhea (CID) among patients with colorectal cancer receiving multi-cycle chemotherapy Dorothy M. KeefeLinda S. EltingStephen T. Sonis Original Article 25 July 2014 Pages: 675 - 680
Long progression-free survival with first-line paclitaxel plus platinum is associated with improved response and progression-free survival with second-line docetaxel in advanced non-small-cell lung cancer Eleazar Omar Macedo-PérezVicente Morales-OyarvideOscar Arrieta Original Article 25 July 2014 Pages: 681 - 690
Treatment of resistant metastatic melanoma using sequential epigenetic therapy (decitabine and panobinostat) combined with chemotherapy (temozolomide) Chang XiaRoberto Leon-FerreMohammed Milhem Original Article Open access 26 July 2014 Pages: 691 - 697
Phase I study of adjuvant gemcitabine or S-1 in patients with biliary tract cancers undergoing major hepatectomy: KHBO1003 study Shogo KobayashiHiroaki NaganoTatsuya Ioka Original Article 30 July 2014 Pages: 699 - 709
Chemotherapy-associated steatohepatitis induced by irinotecan: a novel animal model Marcelo Leite Vieira CostaRoberto César Pereira Lima-JúniorRonaldo Albuquerque Ribeiro Original Article 01 August 2014 Pages: 711 - 720
First-line gefitinib therapy for elderly patients with non-small cell lung cancer harboring EGFR mutation: Central Japan Lung Study Group 0901 Kosuke TakahashiHiroshi SaitoRyujiro Suzuki Original Article 03 August 2014 Pages: 721 - 727
Impact of cytochrome P450 3A4 inducer and inhibitor on the pharmacokinetics of trabectedin in patients with advanced malignancies: open-label, multicenter studies Jean-Pascal MachielsArthur StaddonSunil Sharma Original Article 07 August 2014 Pages: 729 - 737
Investigation of novel circulating proteins, germ line single-nucleotide polymorphisms, and molecular tumor markers as potential efficacy biomarkers of first-line sunitinib therapy for advanced renal cell carcinoma Robert J. MotzerThomas E. HutsonJ. Andrew Williams Original Article Open access 07 August 2014 Pages: 739 - 750
Neoadjuvant chronomodulated capecitabine with radiotherapy in rectal cancer: a phase II brunch regimen study Zuleyha AkgunSezer SaglamEsra Kaytan-Saglam Original Article 08 August 2014 Pages: 751 - 756
Pretherapeutic uracil and dihydrouracil levels in saliva of colorectal cancer patients are associated with toxicity during adjuvant 5-fluorouracil-based chemotherapy Göran CarlssonElisabeth OdinYvonne Wettergren Original Article 08 August 2014 Pages: 757 - 763
A pharmacodynamic model of Bcr–Abl signalling in chronic myeloid leukaemia Robert C. JacksonTomas Radivoyevitch Original Article 09 August 2014 Pages: 765 - 776
Predictive value of APE1, BRCA1, ERCC1 and TUBB3 expression in patients with advanced non-small cell lung cancer (NSCLC) receiving first-line platinum–paclitaxel chemotherapy Zheng LiYi QingDong Wang Original Article 09 August 2014 Pages: 777 - 786
Anticancer activity of VDR-coregulator inhibitor PS121912 Preetpal S. SidhuKelly TeskeLeggy A. Arnold Original Article 09 August 2014 Pages: 787 - 798
Phase II gemcitabine and capecitabine combination therapy in recurrent or metastatic breast cancer patients pretreated with anthracycline and taxane Ji Soo ParkHei-Cheul JeungHyun Cheol Chung Original Article 09 August 2014 Pages: 799 - 808
Resistance to the antiproliferative effect induced by a short-chain ceramide is associated with an increase of glucosylceramide synthase, P-glycoprotein, and multidrug-resistance gene-1 in cervical cancer cells Gisela Gutiérrez-IglesiasYamilec HurtadoRebeca López-Marure Original Article 12 August 2014 Pages: 809 - 817
Population pharmacokinetic and covariate analysis of pertuzumab, a HER2-targeted monoclonal antibody, and evaluation of a fixed, non-weight-based dose in patients with a variety of solid tumors Amit GargAngelica QuartinoBert Lum Original Article 14 August 2014 Pages: 819 - 829
Pharmacokinetics and pharmacogenomics of daunorubicin in children: a report from the Children’s Oncology Group Patrick ThompsonHeather E. WheelerStacey L. Berg Original Article 14 August 2014 Pages: 831 - 838
A prospective study of biomarker-guided chemotherapy in patients with non-small cell lung cancer Qiang ZhangXiaoli ZhuYong Lin Original Article Open access 14 August 2014 Pages: 839 - 846
The combination of Cl-IB-MECA with paclitaxel: a new anti-metastatic therapeutic strategy for melanoma Ana S. SoaresVera M. CostaPaula Fresco Original Article 14 August 2014 Pages: 847 - 860
A pilot study of S-1-based concurrent chemoradiotherapy in patients with biliary tract cancer Hee Man KimKyong Joo LeeSeung Woo Park Original Article 17 August 2014 Pages: 861 - 865
The effect of formulation and food consumption on the bioavailability of dovitinib (TKI258) in patients with advanced solid tumors Sunil SharmaCarolyn D. BrittenDaniel George Clinical Trial Report 06 September 2014 Pages: 867 - 874
Acetyl-l-carnitine (ALCAR) for the prevention of chemotherapy-induced peripheral neuropathy in patients with relapsed or refractory multiple myeloma treated with bortezomib, doxorubicin and low-dose dexamethasone: a study from the Wisconsin Oncology Network Natalie CallanderStephanie MarkovinaShigeki Miyamoto Clinical Trial Report Open access 29 August 2014 Pages: 875 - 882
